sintilimab + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone

This is a multi-agent combination regimen consisting of six drugs: - **Sintilimab** is a monoclonal antibody that acts as an immune checkpoint inhibitor by targeting programmed cell death protein 1 (PD-1), thereby enhancing the immune system's ability to recognize and destroy cancer cells[3][6]. - **Rituximab** is a monoclonal antibody targeting CD20 on B lymphocytes, leading to their depletion. - **Cyclophosphamide**, **doxorubicin**, and **vincristine** are cytotoxic small molecule chemotherapeutic agents with distinct mechanisms—alkylation of DNA, inhibition of topoisomerase II, and disruption of microtubule formation, respectively. - **Prednisone** is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. This combination represents an investigational immunochemotherapy regimen for hematologic malignancies such as diffuse large B-cell lymphoma (DLBCL) or other aggressive lymphomas. The addition of sintilimab aims to enhance antitumor immunity beyond standard chemoimmunotherapy. While similar regimens have been studied (e.g., R-CHOP plus PD-1 inhibitors), this exact combination has not been widely reported in published clinical trials but reflects current trends in combining checkpoint inhibitors with established chemotherapy backbones for improved efficacy[2][3][6].

Brand names

TyvytRituxanMabTheraCytoxanAdriamycinOncovin

Other names

sintlimab + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisoneSintilimab + R-CHOPSintilimab plus R-CHOP